The results from this large cohort study provided naturalistic real-world evidence of the utility of LAIs in patients with schizophrenia and suggest that these agents may help to reduce the risk of relapse across all age groups, especially among younger patients.
Tardive dyskinesia (TD) can be a disfiguring side-effect of antipsychotic medications. In this article the authors review the risk of TD, the potential etiologic mechanisms and present some interesting cases of patients taking atypical antipsychotics who developed TD.
In this article, the authors explore basic sleep physiology, the mechanism of action for each class of hypnotic drugs and their clinical application. The potential pharmacologic sleep-inducing mechanisms of future hypnotics are also described and discussed.
This prospective, observational, non-interventional study conducted in six non-Western countries concludes that after 12 months of treatment, clinical and functional outcomes were improved in children and adolescents with attention deficit hyperactivity disorder (ADHD) who initiated and remained on their prescribed pharmacological monotherapy.
Major depressive disorder (MDD) is a significant public health concern and challenges health care providers to intervene with appropriate treatment. This review provides evidence that duloxetine 60 mg QD is effective for the treatment of adult patients with MDD in the short- and long-term phases of treatment. Duloxetine 60 mg QD also represents a viable choice of treatment for those patients with painful physical symptoms associated with MDD.
